Latest news with #CRD
Yahoo
6 days ago
- Business
- Yahoo
Questcorp Mining Announces Commencement of Phase 1 Work at the La Union Gold Project
Vancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - Questcorp Mining Inc. (CSE: QQQ) (OTCQB: QQCMF) (FSE: D910) (the "Company" or "Questcorp") is pleased to announce the commencement of the first phase work program at its La Union carbonate replacement deposit (CRD) project, located in Sonora, Mexico. Questcorp is earning a 100% interest from Riverside Resources Inc. in the 2,520 ha (25 km sq) property by making a series of cash payments and share issuance and completing a series of exploration expenditures. The initial stages of phase one will concentrate on finalizing the location of drill targets and drill pads for the upcoming drill program. Field activities are underway and include: Establishment of 5 to 6 one kilometre picket lines for IP surveying which commenced on Monday. The IP lines are being run over the heart of some of the past mining areas which continue to be known expansive target areas to help evaluate further potential, possible most favorable zones and assist to model the larger context for the upcoming drill holes. This work further de-risks the up-coming first pass drill holes. Sampling of limestone and dolomite host rocks across the mineralization from country rock through to the heart of mineralization for Black Light analysis and alteration vector modeling. The objective is to use the changes or variance in fluorescence to map alteration patterns to vector into the heart of the manto and chimney plumbing systems. Geological mapping of drill collar sites and section lines particularly along the surface of the IP lines to help develop the most accurate interpretations of the IP data for drill hole planning. Rock and soil sampling of peripheral areas to identify additional targets including study of the stratigraphy for understanding and context with the many mineralization showings on the large district holding. "We are extremely pleased to initiate the fully funded first phase work program at La Union," commented Questcorp President & CEO Saf Dhillon. "We are first concentrating on de-risking the upcoming 1,500 metre drill program scheduled for mid to late Q3 through alteration mapping and IP geophysics," he continued. "Under the technical expertise of John-Mark Staude and the Riverside team we are confident we are maximizing every exploration dollar being invested at La Union," he concluded. Riverside Resources Inc. President & CEO John-Mark Staude stated "The work program is going well, I have been in the field this past week with the exploration team and pleased to see the safe, high quality focus of good work and diving into careful review of the planned drill sites and now the IP program is underway. It is great to work with Saf, Tim and the entire Questcorp organization." The La Union Project The La Union Project is a carbonate replacement deposit ("CRD") project hosted by Neoproterozoic sedimentary rocks (limestones, dolomites, and siliciclastic sediments) overlying crystalline Paleoproterozoic rocks of the Caborca Terrane. The structural setting features high-angle normal faults and low-to-medium-angle thrust faults that sometimes served as mineralization conduits. Mineralization occurs as polymetallic veins, replacement zones (mantos, chimneys), and shear zones with high-grade metal content, as shown in highlight grades of 59.4 grams per metric tonne (g/t) gold, 833 g/t silver, 11% zinc, 5.5% lead, 2.2% copper, along with significant hematite and manganese oxides, consistent with a CRD model (see the technical report entitled "NI 43-101 Technical Report on the Union Project, State of Sonora, Mexico" dated effective May 6, 2025 available under Questcorp's SEDAR+ profile). These targets also demonstrate intriguing potential for large gold discoveries potentially above an even larger porphyry Cu district potential as the Company's target concept at this time. Questcorp cautions investors grab samples are selective by nature and not necessarily indicative of similar mineralization on the property. Riverside, the operator of the La Union Project, is currently lining up the various geophysical contractors to immediately undertake orientation surveys and follow up detailed survey to confirm and enhance the drill targets. The technical and scientific information in this news release has been reviewed and approved by R. Tim Henneberry, P. Geo (BC), a director of the Company and a "qualified person" under National Instrument 43-101 - Standards of Disclosure for Mineral Projects. About Questcorp Mining Inc. Questcorp Mining Inc. is engaged in the business of the acquisition and exploration of mineral properties in North America, with the objective of locating and developing economic precious and base metals properties of merit. The Company holds an option to acquire an undivided 100% interest in and to mineral claims totaling 1,168.09 hectares comprising the North Island Copper Property, on Vancouver Island, British Columbia, subject to a royalty obligation. The Company also holds an option to acquire an undivided 100% interest in and to mineral claims totaling 2,520.2 hectares comprising the La Union Project located in Sonora, Mexico, subject to a royalty obligation. Contact Information Questcorp Mining Dhillon, President & CEOEmail: saf@ (604) 484-3031 This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to Riverside's arrangements with geophysical contractors to undertake orientation surveys and follow up detailed survey to confirm and enhance the drill targets. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the ability of Riverside to secure geophysical contractors to undertake orientation surveys and follow up detailed survey to confirm and enhance the drill targets as contemplated or at all, general business, economic, competitive, political and social uncertainties, uncertain capital markets; and delay or failure to receive board or regulatory approvals. There can be no assurance that the geophysical surveys will be completed as contemplated or at all and that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
6 days ago
- Health
- Business Wire
Cure Rare Disease Receives FDA Feedback on Limb-Girdle 2i/R9 Gene Therapy Program Following Successful Pre-IND Meeting
WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD), a nonprofit biotechnology organization developing genetic therapies for ultra-rare diseases, today announced the successful completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding its investigational gene therapy program for Limb-Girdle Muscular Dystrophy type 2I/R9 (LGMDR9). The LGMDR9 program, known as CRD-003, utilizes a novel, engineered AAVMYO2 capsid to deliver a functional copy of the FKRP gene. Murine and non-human primate studies support that AAVMYO2 de-targets the liver while offering enhanced muscle tropism which allows for a reduction of the clinical dose. CRD-003 is designed for patients with LGMDR9 caused by mutations in the FKRP gene, a condition that leads to progressive muscle weakness and loss of ambulation. CRD-003 is intended to be administered as a single intravenous injection and is among the first gene therapy candidates tailored to this rare neuromuscular disease population using a next-generation AAV capsid. Following the pre-IND interaction, the FDA provided written feedback across key domains including Chemistry, Manufacturing, and Controls (CMC), nonclinical development, and clinical trial design. The agency supported CRD's overall development approach while offering constructive guidance to further strengthen the planned Investigational New Drug (IND) submission. Notably: The FDA agreed that a 4-month murine GLP toxicology study, incorporating acute and chronic toxicity assessments, could be sufficient to support initiation of the first-in-human trial. The agency endorsed the proposed clinical trial design and patient selection strategy, and deemed the biomarker strategy—evaluating glycosylation changes and muscle MRI—appropriate. The agency suggested that CRD-003 may seek accelerated approval on the basis of results from the Phase I/II clinical trial, pending results 'Receiving FDA feedback is a critical milestone as we advance CRD-003 toward the clinic,' said Rich Horgan, Founder and CEO of Cure Rare Disease. 'Early and proactive engagement with the FDA is a cornerstone of our drug development strategy. It ensures that our programs are aligned with regulatory expectations from the outset, allowing us to prioritize both patient safety and operational efficiency. This collaborative dialogue helps us navigate the complexities of developing therapies for rare diseases while furthering our ability to bring much-needed treatments to the individuals who need them most.' With this milestone completed, CRD will continue executing its IND-enabling studies, incorporating FDA recommendations, and preparing for IND submission. About Cure Rare Disease Cure Rare Disease, a 501(c)(3) nonprofit biotechnology company based in Woodbridge, CT, is transforming possibilities for people with ultra-rare diseases by developing advanced therapeutics in time to save lives. Through a collaborative community of forward-thinking families, patients, scientists and supporters, Cure Rare Disease has enabled an ecosystem of innovation and discovery to overcome the obstacles inherent in existing models of medicine and to expedite life-saving genetic technologies from research to the clinic. For more information, please visit
Globe and Mail
6 days ago
- Business
- Globe and Mail
Ridgeline Minerals Commences Drill Program at the Selena CRD Project, Nevada
Vancouver, British Columbia--(Newsfile Corp. - June 23, 2025) - Ridgeline Minerals Corp. (TSXV: RDG) (OTCQB: RDGMF) (FSE: 0GC0) (" Ridgeline" or the " Company") is pleased to announce the commencement of its 2025 drill program at the Selena Carbonate Replacement ("CRD") project ("Selena" or "Project") (Figure 1). The Project is currently being operated by Ridgeline under Phase 1 of an earn-in agreement with a wholly owned subsidiary of South32 Limited ("South32"). All dollars noted are US dollars. South32 has approved a Year-2 exploration budget of $3,450,000 to drill up to three deep core holes (4,500 metres total) targeting the highly conductive Magnetotellurics ("MT") anomaly that was identified at the Chinchilla Sulfide CRD target (Figure 2) in early 2025. All three core holes will target specific stratigraphic and structural horizons across the known strike of the MT anomaly, with the first of three holes targeting the shallowest expression of the Chinchilla Sulfide target. The anomaly plunges roughly 45 degrees north to south and is bound on both sides by a series of east verging thrust faults, interpreted as key fluid conduits to the CRD system (Figure 3). Figure 1: Plan view map of the Selena project showing the locations of the three planned core holes (red stars) that will test the multikilometer-scale MT anomaly at the Chinchilla Sulfide target. To view an enhanced version of this graphic, please visit: Figure 2: Simplified Long Section A-A' showing planned core hole #2 (1,600m) testing the highly conductive MT anomaly on both sides of the interpreted thrust faults, which are inferred as key structural controls to the CRD system. To view an enhanced version of this graphic, please visit: Figure 3: Simplified Chinchilla Sulfide Cross Section B-B' showing planned core holes 1-3 testing the 2+ kilometer strike extent of the MT anomaly, which is interpreted as a highly conductive sulfide CRD target. To view an enhanced version of this graphic, please visit: QA/QC Procedures Samples are submitted to American Assay Laboratories (AAL) of Sparks, Nevada, which is a certified and accredited laboratory, independent of the Company. Independent check samples are sent to Paragon Geochemical Labs (PAL) of Sparks, Nevada. Samples are prepared using industry-standard prep methods and analysed using FA-PB30-ICP (Au; 30g fire assay) and ICP-5AM48 (48 element Suite; 0.5g 5-acid digestion/ICP-MS) methods. AAL also undertakes its own internal coarse and pulp duplicate analysis to ensure proper sample preparation and equipment calibration. Ridgeline's QA/QC program includes regular insertion of CRM standards, duplicates, and blanks into the sample stream with a stringent review of all results completed by the Company's Qualified Person, Michael T. Harp, Vice President, Exploration. The technical information contained in this news release has been prepared under the supervision of, and approved by Michael T. Harp, CPG, the Company's Vice President, Exploration. Mr. Harp is a "qualified person" as defined under National Instrument 43-101 - Standards of Disclosure for Mineral Projects. Selena Project Selena is located in White Pine County, Nevada, approximately 64 kilometers ("km") north of the town of Ely, NV. The Project is currently being operated by Ridgeline under Phase 1 of an earn-in agreement with a wholly owned subsidiary of South32 Limited ("South32") and shares a property boundary with the Butte Valley project, a $33M earn-in agreement between Freeport-McMoRan and the underlying owner, Falcon Butte Minerals. The Project is comprised of 39 square kilometers of highly prospective exploration ground including Ridgeline's shallow-oxide Ag-Au ± Pb-Zn Chinchilla Oxide and deeper Chinchilla Sulfide discoveries. Subsequent drilling has continued to highlight the potential for high-grade CRD type mineralization (Ag-Au-Pb-Zn ±Cu-W) between Chinchilla Oxide and Freeport-McMoRan's Butte Valley Cu-Au-Ag-Zn porphyry located directly west of the property (View the Selena VRIFY Deck Here). For additional information regarding the South32 earn-in agreement terms, view the August 22, 2024 news release HERE. About Ridgeline Minerals Corp. Ridgeline Minerals is a discovery focused precious and base metal explorer with a proven management team and a 200 km 2 exploration portfolio across seven projects in Nevada, USA. The Company is a hybrid explorer with a mix of 100%-owned exploration assets (Big Blue, Atlas, Bell Creek & Coyote) as well as two earn-in exploration agreements with Nevada Gold Mines at its Swift and Black Ridge projects and a third earn-in with South32 at its Selena project. More information about Ridgeline can be found at On behalf of the Board "Chad Peters" President & CEO Further Information: Chad Peters, President, CEO & Director Ridgeline Minerals Corp. +1 775 304 9773 cpeters@ Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release Cautionary Note regarding Forward-Looking Statements Statements contained in this press release that are not historical facts are "forward-looking information" or "forward-looking statements" (collectively, "Forward-Looking Information") within the meaning of applicable Canadian securities legislation and the United States Private Securities Litigation Reform Act of 1995. Forward-Looking Information includes, but is not limited to, the anticipated benefits of the Earn-In Agreement and the transaction contemplated thereby. The words "potential", "anticipate", "meaningful", "discovery", "forecast", "believe", "estimate", "expect", "may", "will", "project", "plan", "historical", "historic" and similar expressions are intended to be among the statements that identify Forward-Looking Information. Forward-Looking Information involves known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from any future results expressed or implied by the Forward-Looking Information. In preparing the Forward-Looking Information in this news release, Ridgeline has applied several material assumptions, including, but not limited to, assumptions that TSX Venture Exchange approval will be granted in a timely manner subject only to standard conditions; the current objectives concerning the Project can be achieved and that its other corporate activities will proceed as expected; that general business and economic conditions will not change in a materially adverse manner; and that all requisite information will be available in a timely manner. Forward-Looking Information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of Ridgeline to be materially different from any future results, performance or achievements expressed or implied by the Forward-Looking Information. Such risks and other factors include, among others, risks related to dependence on key personnel; risks related to unforeseen delays; risks related to historical data that has not been verified by the Company; as well as those factors discussed in Ridgeline's public disclosure record. Although Ridgeline has attempted to identify important factors that could affect Ridgeline and may cause actual actions, events, or results to differ materially from those described in Forward-Looking Information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that Forward-Looking Information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on Forward-Looking Information. Except as required by law, Ridgeline does not assume any obligation to release publicly any revisions to Forward-Looking Information contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Medscape
17-06-2025
- Health
- Medscape
Why Is Europe Neglecting Chronic Respiratory Disease?
The magnitude of chronic respiratory diseases (CRDs) across Europe has been overlooked, leading to under- and misdiagnosis, poor management, and inadequate funding, according to a new report. Published by the World Health Organization (WHO) Europe and the European Respiratory Society, the report found that 81.7 million people in the region are living with a CRD — including chronic obstructive pulmonary disease (COPD), asthma, and other lung diseases — and 6.8 million are newly diagnosed each year. CRDs are the sixth leading cause of death in the WHO European region, with almost 400,000 dying from a CRD every year, nearly 80% of which are caused by COPD. However, most of these deaths are driven by preventable risk factors, primarily tobacco use and indoor and outdoor air pollution. The region has one of the highest rates of tobacco use, with one fourth of its adults being smokers, and more than 90% breathing air that is polluted with dangerous levels of particulate matter. Answering the Whys So why are CRDs so vastly underdiagnosed in Europe? Why do healthcare professionals not have the skills and expertise to identify them, as stated in the report? And what resources are required to bridge this gap? On a policy level, the report noted an important paradox: Earlier progress led to a decline in CRD mortality, but this consequently led to reduced research funding and weakened surveillance. Without understanding the true burden of disease, it is difficult to advocate for increased policy focus and additional funding. 'Unfortunately, due to complexity with their definitions and absence of unanimously agreed targets, CRD surveillance and monitoring systems are not well designed,' the report said. 'Determining the real magnitude of the CRD burden is fundamental to identifying unmet needs at population level.' 'There has been a reduction in investment for CRD research compared with other noncommunicable diseases, where epidemiological studies have defined their global burden and priority actions; there are only a handful of population-based studies on CRDs,' the report continued. Numerous health system and health worker challenges prevent the timely and correct diagnosis of CRDs. These include overlapping symptoms with other respiratory conditions and frequent comorbidities; limited healthcare provider knowledge and skills, especially at the primary healthcare level; inadequate access to diagnostic tools; lack of respiratory health specialists; and lack of awareness among patients, all of which can contribute to under- and misdiagnosis and thus delays in accessing treatment. Respiratory Diseases Not so Glamorous Philip Bardin, FRACP, PhD, professor and director of Lung and Sleep Medicine at Monash University and Medical Centre, Melbourne, Australia, and an international authority in the field of asthma and COPD, told Medscape Medical News that the impact of CRDs in the community has long been underappreciated. Philip Bardin, FRACP, PhD 'We compete in the health space with other chronic diseases that use shock and awe tactics such as: 'You will have a stroke, a heart attack, or your foot will fall off' to gain public attention and funding,' he said. 'Historically, [there has been] poor advocacy by craft groups.' Peter Burney, MD, professor of respiratory epidemiology and public health at the National Heart and Lung Institute at Imperial College London and honorary consultant physician at Royal Brompton Hospital, London, England, echoed Bardin's thoughts. Peter Burney, MD 'Respiratory diseases are not glamourous; there is little sympathy for the old and the poor, and even less if they have been smokers. Asthma research has always been better funded with publicity that focuses on childhood [exposure to] smoking. Governments ought to be spurred on by the high costs of COPD in [terms of] direct costs of hospitalization.' He cited a 2015 study published in the journal Chest that reviewed population-based prevalence studies that measured lung function and looked for undiagnosed COPD. Undiagnosed COPD was high in almost all locations studied, he said. 'London (UK) had a high prevalence of disease, but approximately 80% [of detected COPD cases were] undiagnosed. The why is complicated,' he said. 'Firstly, COPD is a very recent invention, and chronic obstructive pulmonary disease may mean more to average Americans than others. We used to call it bronchitis or chronic obstructive bronchitis.' The Primary Care Challenge With a shortage of respiratory specialists, some countries are expanding the role of primary healthcare to include the identification of CRDs, joining many other countries that have for decades put primary providers on the front line of respiratory medicine. But while spirometry is one of the essential tools for diagnosing and monitoring CRDs, it remains limited as it requires well-trained staff, reliable equipment, and standardized procedures. 'Spirometry is not commonly done in general practice, and it was more or less stopped during COVID. It is difficult to do well, and quality assurance is a problem,' Burney said. 'If a practitioner is not using skills learned in medical school and in early training, the skill in interpreting spirometry results soon atrophies. In addition, primary care is feeling a bit put upon, and it is difficult in these circumstances to launch a whole new initiative.' Promise in Education Expanding education and using innovative technology appear to hold some promise in overcoming such challenges. The report cited Spain, which has a new e-learning program, Spirometry Simplified, for primary healthcare providers to expand their knowledge. Also, Italy and Spain are testing tele-spirometry. Here, a technician remotely controls from within a hospital a computer with spirometer software that is connected to a primary care patient. The aim is to help overcome the issue of poor-quality spirometry use in primary care. 'Solutions need to come via patient participation and teamwork by doctors, nurses, and others to improve care. Waiting for governments and bureaucrats to solve problems will take us nowhere,' Bardin said. 'Doing better what we've always done will get us what we've always had.' Bardin and Burney reported having no relevant financial relationships.
Yahoo
10-06-2025
- Entertainment
- Yahoo
Justin Baldoni's Lawyer Says Blake Lively's Victory Is 'False'
Originally appeared on E! Online Justin Baldoni's lawyer has a lot more to say. One day after the It Ends With Us director's $400 million countersuit against Blake Lively—as well as her husband Ryan Reynolds and publicist Leslie Sloane—was officially dismissed by a judge June 9, his attorney stressed that the legal battle is far from over. 'Ms. Lively and her team's predictable declaration of victory is false,,' Baldoni's lawyer Bryan Freedman said in a statement to E! News June 10. 'So let us be clear about the latest ruling.' Indeed, in legal documents obtained by E! News, judge Lewis J. Liman ruled that Baldoni and his associates had failed to prove defamation in their filing and to prove that 'Lively's threats were wrongful extortion rather than legally permissible hard bargaining or renegotiation of working conditions.' (Baldoni's $250 million lawsuit against was also dismissed.) However, the judge ruled that Baldoni can refile an amended complaint on the allegations of tortious interference with contract, relating to Reynolds and Lively, and breach of implied covenant, relating to Lively by June 23. And, according to Freedman, Baldoni's case against Lively goes far deeper than his dismissed claims of defamation. More from E! Online Justin Bieber Slams "Transactional Relationships' After Hailey Bieber Split Rumors Glen Powell's Ex Gigi Paris Breaks Silence on Sydney Sweeney Romance Rumors Are Taylor Swift and Travis Kelce Married? Here's the Truth 'This case is about false accusations of sexual harassment and retaliation and a nonexistent smear campaign, which Ms. Lively's own team conveniently describes as 'untraceable' because they cannot prove what never happened,' Freedman continued. 'Most importantly, Ms. Lively's own claims are no truer today than they were yesterday, and with the facts on our side, we march forward with the same confidence that we had when Ms. Lively and her cohorts initiated this battle and look forward to her forthcoming deposition, which I will be taking.' Meanwhile, Lively—who sued Baldoni in January for emotional distress and loss of wages that she says occurred during the filming of It Ends With Us—went on to share gratitude for the support she received following Baldoni's initial filing. 'Like so many others, I've felt the pain of a retaliatory lawsuit, including the manufactured shame that tries to break us,' Lively wrote in a June 9 statement on her Instagram Story. 'While the suit against me was defeated, so many don't have the resources to fight back.' Following her legal win, Lively said she was 'more resolved than ever' to stand for women's rights to protect themselves, and went on to share resources. She concluded with a note to those who supported her in her own legal endeavor, 'I will never stop appreciating or advocating for you.' Keep reading for the latest in the ongoing legal battle between Baldoni and Lively… Dec. 20, 2024: Blake Lively Files CRD Complaint Against Justin Baldoni and His Wayfarer AssociatesDec. 21, 2024: The New York Times Publishes Report About the Alleged Smear Campaign Against LivelyDec. 21, 2024: Baldoni and Wayfarer's Attorney Responds to Lively's CRD ComplaintDec. 21, 2024: Baldoni Is Dropped by Talent AgencyDec. 21, 2024: It Ends With Us Cast Members and More Stars React to Lively's Allegations Against BaldoniDec. 23, 2024: Baldoni and Heath's Cohost on The Man Enough Podcast Leaves ShowDec. 24, 2024: Baldoni's Former Publicist Sues Him, Abel, Nathan and Wayfarer Dec. 31, 2024: Baldoni, Wayfarer & Others Sue The New York TimesDec. 31, 2024: Lively Files Lawsuit Against Baldoni and Wayfarer AssociatesJan. 2, 2025: Baldoni's Lawyer Expresses Intent to Sue LivelyJan. 7, 2025: Baldoni's Lawyer Calls Out Deadpool & WolverineJan. 16, 2025: Baldoni, Wayfarer, Nathan & Abel File Lawsuit Against Lively, Reynolds & OthersJan. 16, 2025: Lively's Lawyers Slam Baldoni's "Desperate" LawsuitJan. 21, 2025: Behind-the-Scenes Footage of It Ends With Us ReleasedJan. 22, 2025: Lively and Reynolds Seek Gag Order on Baldoni's LawyerJan. 27, 2025: Baldoni's 2 AM Voice Memo to Lively RevealedJan. 27, 2025: Lively vs. Baldoni Trial SetJan. 31, 2025: Baldoni Adds The New York Times to $400 Million LawsuitFeb. 2, 2025: Baldoni's Team Launches a WebsiteFeb. 18, 2025: Lively Files Her Own Amended ComplaintFeb. 20, 2025: Lively and Reynold's Publicist Asks to Be Dropped From Lawsuit For the latest breaking news updates, click here to download the E! News App
